SinoMab BioScience Limited (HKG:3681)
Hong Kong · Delayed Price · Currency is HKD 1.125
-0.025 (-2.17%)
Sep 18, 2026, 3:54 PM HKT
SinoMab BioScience Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | - | - | 2.03 | 1.37 | - | 25.91 |
Other Revenue | - | - | - | - | 4.03 | 0.74 |
| - | - | 2.03 | 1.37 | 4.03 | 26.66 | |
Revenue Growth | - | - | 48.43% | -66.15% | -84.88% | 108.91% |
Cost of Revenue | - | - | 1.48 | 0.94 | - | - |
Gross Profit | - | - | 0.54 | 0.42 | 4.03 | 26.66 |
Selling, General & Admin | 61.66 | 46.38 | 67.72 | 97.62 | 82.59 | 133.4 |
Research & Development | 99.22 | 81.62 | 94.75 | 135.41 | 180.37 | 199.11 |
Operating Expenses | 160.88 | 128.01 | 162.47 | 233.02 | 262.96 | 332.51 |
Operating Income | -160.88 | -128.01 | -161.93 | -232.6 | -258.93 | -305.86 |
Interest Expense | -5.85 | -5.53 | -8.66 | -6.58 | -4.96 | -5.82 |
Interest & Investment Income | 3.71 | 3.71 | 5.88 | 6.18 | 9.58 | 16.73 |
Earnings From Equity Investments | - | - | - | - | -5.4 | -4.29 |
Currency Exchange Gain (Loss) | 11.39 | 11.39 | -9.47 | -12.81 | -61.89 | 9.88 |
Other Non Operating Income (Expenses) | 18.67 | 5.4 | 1.04 | 3.74 | 0.59 | 1.16 |
EBT Excluding Unusual Items | -132.96 | -113.03 | -173.14 | -242.08 | -321.01 | -288.19 |
Gain (Loss) on Sale of Investments | 0.73 | 0.73 | 0.5 | - | 39.77 | - |
Gain (Loss) on Sale of Assets | -1.39 | -0.09 | 0.08 | - | -1.44 | - |
Asset Writedown | -56.34 | - | - | - | -1.48 | - |
Other Unusual Items | 7.41 | 7.41 | -12.58 | -1.03 | - | - |
Pretax Income | -182.55 | -104.99 | -185.14 | -243.11 | -284.16 | -288.19 |
Earnings From Continuing Operations | -182.55 | -104.99 | -185.14 | -243.11 | -284.16 | -288.19 |
Net Income | -182.55 | -104.99 | -185.14 | -243.11 | -284.16 | -288.19 |
Net Income to Common | -182.55 | -104.99 | -185.14 | -243.11 | -284.16 | -288.19 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 1,365 | 1,227 | 1,074 | 1,018 | 992 | 995 |
Shares Outstanding (Diluted) | 1,365 | 1,227 | 1,074 | 1,018 | 992 | 995 |
Shares Change | 25.65% | 14.30% | 5.46% | 2.64% | -0.29% | -1.13% |
EPS (Basic) | -0.13 | -0.09 | -0.17 | -0.24 | -0.29 | -0.29 |
EPS (Diluted) | -0.13 | -0.09 | -0.17 | -0.24 | -0.29 | -0.29 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -98.5 | -95.5 | -171.97 | -237.19 | -413.29 | -345.3 |
Free Cash Flow Per Share | -0.07 | -0.08 | -0.16 | -0.23 | -0.42 | -0.35 |
Gross Margin | - | - | 26.80% | 30.92% | 100.00% | 100.00% |
Operating Margin | - | - | -7992.40% | -17040.44% | -6421.80% | -1147.38% |
Profit Margin | - | - | -9138.25% | -17810.33% | -7047.57% | -1081.12% |
Free Cash Flow Margin | - | - | -8487.96% | -17376.19% | -10250.22% | -1295.33% |
EBITDA | -148.24 | -114.63 | -147.07 | -213.47 | -244.29 | -296.43 |
D&A For EBITDA | 12.64 | 13.38 | 14.86 | 19.13 | 14.63 | 9.43 |
EBIT | -160.88 | -128.01 | -161.93 | -232.6 | -258.93 | -305.86 |